Sumitomo Pharma Co., Ltd. (TSE: 4506)
Health Care · Pharmaceuticals · JP
¥1,411.50
+2.88% today · -2.0% 1Y
Sumitomo Pharma Co., Ltd. (TSE: 4506) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $3.98B and employs 3,123 people.
Over the last twelve months the share price has lost 2.0%, trading between 1.19K and 3.29K.
Tweenvest scores Sumitomo Pharma Co., Ltd. across four factors: quality 66/100, value 57/100, growth 51/100. Its strongest factor is quality.
4506 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.98B
- Revenue (TTM)
- $2.92B
- P/E
- 5.10
- EPS
- 276.88
- Dividend yield
- —
- Beta (5Y)
- 0.46
- 52-week high
- ¥3,288.00
- 52-week low
- ¥1,188.00
- Avg volume (3M)
- —
- Shares outstanding
- 448.59M
- Employees
- 3,123
- Next earnings
- —
About Sumitomo Pharma Co., Ltd.
Sumitomo Pharma Co., Ltd. is a global company involved in the creation, production, and sale of a variety of products, including human pharmaceuticals, food ingredients and additives, and veterinary medicines. Its operations span across Japan, North America, China, and other international territories. The company's pharmaceutical offerings address a broad spectrum of medical needs. These include treatments for conditions such as Parkinson's disease, depression, type 2 diabetes, systemic fungal infections, hypertension, pruritus, chronic obstructive pulmonary disease (COPD), angina pectoris, and arrhythmia. Additionally, they manufacture atypical antipsychotics, antiepileptics, carbapenem antibiotics, gastrointestinal products, and specialized medications for Anderson-Fabry disease. Beyond healthcare, Sumitomo Pharma provides food components and enhancement agents like polysaccharides, along with savory flavorings such as soups and bouillons. The company also supplies chemical raw materials, which encompass pharmaceutical excipients, components for personal care products, substances used in coatings and industrial applications, and electronic materials. Moreover, it produces veterinary therapeutic solutions designed for domestic pets, specifically dogs and cats, as well as for various farm animals, including cattle, swine, poultry, horses, and cultivated fish. To drive innovation, Sumitomo Pharma fosters partnerships with several organizations. These collaborators include Healios K.K., Keio University, RIKEN, the Center for iPS Cell Research and Application, Kyoto University, and Aikomi Co., Ltd. The company also maintains a joint development agreement with SanBio Company Limited, a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd., and a strategic alliance with Roivant Sciences Ltd. Originally established in 1897, the company, headquartered in Osaka, Japan, was known as Sumitomo Dainippon Pharma Co., Ltd. until it adopted its current name, Sumitomo Pharma Co., Ltd., in April 2022. It functions as a subsidiary of Sumitomo Chemical Company, Limited.
- ISIN
- JP3495000006
- Founded
- 1897
- Listed since
- Jan 4, 2000
- Exchange
- The Tokyo Stock Exchange
- Currency
- JPY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,233.66 | -1.06% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.14 | +0.04% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $156.45 | +3.84% |
| Roche Holding AGSWX: ROP | $371.62B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.57 | +2.15% |
Figures last refreshed Aug 18, 2026.